^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    FLM-7523

    i
    Other names: FLM-7523, FTX-001, MALAT-1 targeted ASO, FLM7523, FLM 7523, FTX001, FTX 001
    Associations

    News

    Trials
    Company:
    Flamingo Therapeutics
    Drug class:
    IncRNA modulator, MALAT1 inhibitor
    Associations

    News

    Trials
    almost3years
    Preclinical development of FTX-001: first in class inhibitor of the long non-coding RNA MALAT1 (AACR 2023)
    Ongoing histopathological evaluation will complete the health hazard evaluation of FTX-001. Taken together, these results demonstrate the high potency and good preclinical safety profile of FTX-001 which supports the potential to achieve good target engagement (MALAT1 RNA knock down in human tumors) at well tolerated clinical doses in cancer patients.
    Preclinical
    |
    MALAT1 (Metastasis associated lung adenocarcinoma transcript 1)
    |
    FLM-7523